TSE:4536Pharmaceuticals
Santen Pharmaceutical (TSE:4536) Margin Improvement Reinforces Earnings Growth Narrative
Santen Pharmaceutical (TSE:4536) has reported another quarter, with Q3 2026 revenue at ¥72,884 million and basic EPS of ¥24.49, while trailing twelve month revenue is ¥287,994 million and EPS is ¥92.02. The company’s revenue moved from ¥76,369 million in Q3 2025 to ¥72,884 million in Q3 2026, with basic EPS shifting from ¥25.32 to ¥24.49 over the same period. This provides context for assessing how these earnings and margins relate to the current share price of ¥1,719. With earnings over the...